Toward a New Paradigm for the Identification and Functional Characterization of von Willebrand Disease

被引:38
作者
Favaloro, Emmanuel J. [1 ]
机构
[1] SWAHS, Westmead Hosp, Dept Haematol, ICPMR, Westmead, NSW 2145, Australia
关键词
Desmopressin; DDAVP; von Willebrand factor; VWF; von Willebrand disease; VWD; diagnosis; classification; COLLAGEN-BINDING ASSAY; CENTER DOCTORS ORGANIZATION; CLINICAL MARKERS; FACTOR SURVIVAL; TYPE-1; VWD; LABORATORY DIAGNOSIS; DESMOPRESSIN DDAVP; FACTOR PROPEPTIDE; MANAGEMENT; THERAPY;
D O I
10.1055/s-0029-1214149
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The diagnosis and functional characterization of von Willebrand disease (VWD) is challenging. There are inherent difficulties in both its identification and classification because of clinical uncertainty, the limitations in the test processes and test panels typically used by laboratories, and because the classification scheme does not always allow unequivocal assignment of any subtype. This article reviews current thoughts and alternatives to the classic approach of the classification and functional characterization of VWD. Of particular interest to this author is the utility of an extended core test panel that includes additional functional VWF assays, such as the collagen binding assay, and the potential for desmopressin (DDAVP) challenge to not only provide therapeutic information but also assist in the better characterization of individuals with defects or deficiencies in von Willebrand factor (VWF). The potential use of supplementary assays Such as the PFA-100 and the VWF propeptide assay after DDAVP challenge is also worth noting.
引用
收藏
页码:60 / 75
页数:16
相关论文
共 49 条
[1]   Diagnosing von Willebrand disease: A large reference laboratory's perspective [J].
Adcock, Dorothy M. ;
Bethel, Melissa ;
Valcour, Andre .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (05) :472-479
[2]   Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans [J].
Borchiellini, A ;
Fijnvandraat, K ;
tenCate, JW ;
Pajkrt, D ;
vanDeventer, SJH ;
Pasterkamp, G ;
MeijerHuizinga, F ;
ZwartHuinink, L ;
Voorberg, J ;
vanMourik, JA .
BLOOD, 1996, 88 (08) :2951-2958
[3]   Reduced von Willebrand factor survival in type Vicenza von Willebrand disease [J].
Casonato, A ;
Pontara, E ;
Sartorello, F ;
Cattini, MG ;
Sartori, MT ;
Padrini, R ;
Girolami, A .
BLOOD, 2002, 99 (01) :180-184
[4]   An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type I von Willebrand disease [J].
Cumming, Anthony ;
Grundy, Pamela ;
Keeney, Stephen ;
Lester, William ;
Enayat, Said ;
Guilliatt, Andrea ;
Bowen, Derrick ;
Pasi, John ;
Keeling, David ;
Hill, Frank ;
Bolton-Maggs, Paula H. B. ;
Hay, Charles ;
Collins, Peter .
THROMBOSIS AND HAEMOSTASIS, 2006, 96 (05) :630-641
[5]  
DUNCAN EM, 2008, INT J LAB HEMAT 0321
[6]   Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal [J].
Favaloro, E. J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (11) :1999-2001
[7]   VON WILLEBRANDS DISEASE - USE OF COLLAGEN-BINDING ASSAY PROVIDES POTENTIAL IMPROVEMENT TO LABORATORY MONITORING OF DESMOPRESSIN (DDAVP) THERAPY [J].
FAVALORO, EJ ;
DEAN, M ;
GRISPO, L ;
EXNER, T ;
KOUTTS, J .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 45 (03) :205-211
[8]   Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy:: efficacy of the PFA-100® and vWF:CBA as combined diagnostic strategies [J].
Favaloro, EJ ;
Kershaw, G ;
Bukuya, M ;
Hertzberg, M ;
Koutts, J .
HAEMOPHILIA, 2001, 7 (02) :180-189
[9]  
FAVALORO EJ, 2008, THROMB RES 1207
[10]   A better approach to monitoring of therapy in von Willebrand disease? [J].
Favaloro, Emmanuel J. .
THROMBOSIS AND HAEMOSTASIS, 2008, 100 (03) :371-373